Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications

Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer-A Systematic Review and Meta-Analysis.

Efficacy and Safety of Antibody Drug Conjugates in Previously Treated Hormone Receptor Positive HER2 Negative (or Low) Metastatic Breast Cancer-A Systematic Review and Meta-Analysis.

Journal: American journal of clinical oncology
Published: October 14, 2025

Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.

Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.

Journal: Przeglad menopauzalny = Menopause review
Published: August 24, 2025

Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives.

Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives.

Journal: Cancer treatment reviews
Published: August 21, 2025

Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.

Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention.

Journal: International reviews of immunology
Published: August 19, 2025

Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.

Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers.

Journal: Expert review of clinical pharmacology
Published: July 15, 2025

Datopotamab deruxtecan induces hallmarks of immunogenic cell death.

Datopotamab deruxtecan induces hallmarks of immunogenic cell death.

Journal: Cell stress
Published: July 03, 2025

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Journal: Gynecologic oncology
Published: July 02, 2025

Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer.

Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer.

Journal: Oncology and therapy
Published: July 02, 2025

An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer.

An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer.

Journal: Expert opinion on biological therapy
Published: June 14, 2025

Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.

Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.

Journal: International journal of molecular sciences
Published: June 11, 2025

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.

Journal: The Journal of thoracic and cardiovascular surgery
Published: June 09, 2025

The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations.

The tricky effects of TROP2 in lung cancer: from clinical practice back to fundamental investigations.

Journal: Frontiers in oncology
Published: May 30, 2025
Showing 1-12 of 82

Last Updated: 10/31/2025